hero-logo

RNA-based medicines for hearing loss. Delivered.

menu-icon
border-img about-us

About

The WHO predicts hearing loss will impact 1 in 10 people by 2050. Medical devices are the standard of care, but they are ineffective for many people.

Despite a prevalence greater than cancer or diabetes, there are currently no treatments available to treat the underlying cellular dysfunction which is the root cause of hearing loss.

Lipid nanoparticle-based mRNA therapeutics were spectacularly validated as a mass market medicine through the COVID-19 pandemic. We believe the time is now to create the world’s first mass market medicine for hearing loss.

Technology

Our lipid nanoparticle based mRNA technology enables us to deliver therapeutic proteins for regeneration and protection of key cells in the cochlea, all at a cost that will make it feasible to create an accessible mass market medicine.

border-img about-us
technology-infographic

Team

A founding team of world-class scientists, surgeons and entrepreneurs

team-member

Arpan Desai PhD CEO

team-member

Prof Manohar Bance MBChB MSc FRCS FRCSC ABOto

team-member

Sunil Shah MBA Board Chair

team-member

Nikola Dubrowska BSc

team-member

Dr Matthew Smith MBBChir MA PhD FRCS (ORL-HNS)

team-member

Dr Alan Foster

history-img

Collaborators

partner-image
partner-image
partner-image
partner-image
partner-image